Updates from The Motley Fool

Latest updates on Emergent BioSolutions from Fool.com.

Stock Performance

EBS vs. S&P 500 | 2 Year Performance
EBS 1-Day Stock Chart
EBS 5-Day Stock Chart
EBS 1-Month Stock Chart
EBS 3-Month Stock Chart
EBS 6-Month Stock Chart
EBS 1-Year Stock Chart
EBS 2-Year Stock Chart
EBS 5-Year Stock Chart
View Interactive EBS Charts
Sponsored by

Key Data Points

Primary metrics and data points about Emergent BioSolutions.
Current Price: $43.70
Prev Close: $43.15
Open: $43.13
Bid: $39.64
Ask: $43.83
Day's Range: $42.81 - $43.70
52wk Range: $27.68 - $43.70
Volume: 304,015
Avg Vol 476,954
Market Cap: $1.70B
P/E (ttm): 18.76
EPS (ttm): $2.30
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Emergent BioSolutions.
CAPS Rating 4 out of 5
479 Outperform
17 Underperform
CAPS All Stars
85 Outperform
5 Underperform

How do you think Emergent BioSolutions will perform against the market?

You pick for Emergent BioSolutions is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS

CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Daniel J. Abdun-Nabi, CEO

60% Approve

Based on 50 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Emergent BioSolutions.

Emergent BioSolutions makes the only FDA-approved anthrax vaccine.

  • Exchange: NYSE
  • Sector: Healthcare
  • Industry: Drug Makers